| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MGC117399 |
| Entrez GeneID | 335 |
| clone | 5F4F5 |
| WB Predicted band size | 25kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human APOA1 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于APOA1抗体的3篇虚构参考文献(仅供示例，非真实文献)：
1. **文献名称**：*Autoantibodies to Apolipoprotein A-1 in Cardiovascular Diseases*
**作者**：Smith J. et al.
**摘要**：研究揭示了抗APOA1抗体在动脉粥样硬化中的病理作用，发现其通过干扰HDL功能促进炎症反应和斑块不稳定性。
2. **文献名称**：*APOA1 Antibodies as Biomarkers in Systemic Lupus Erythematosus*
**作者**：Chen L. et al.
**摘要**：探讨了系统性红斑狼疮患者血清中抗APOA1抗体的高表达及其与疾病活动度和肾脏损伤的相关性。
3. **文献名称**：*Diagnostic Potential of Anti-APOA1 Antibodies in Colorectal Cancer*
**作者**：Wang Y. et al.
**摘要**：提出抗APOA1抗体可作为结直肠癌早期诊断的生物标志物，其水平与肿瘤进展和预后显著相关。
(注：以上内容为模拟示例，实际文献需通过学术数据库检索。)
APOA1 (Apolipoprotein A1) is the primary structural protein of high-density lipoprotein (HDL), often referred to as "good cholesterol." Synthesized in the liver and intestines, APOA1 plays a critical role in lipid metabolism by promoting cholesterol efflux from peripheral tissues to the liver for excretion—a process known as reverse cholesterol transport (RCT). This function underlies its cardioprotective properties, as impaired RCT is linked to atherosclerosis and cardiovascular diseases. APOA1 also exhibits anti-inflammatory, antioxidant, and anti-apoptotic effects, contributing to vascular health.
APOA1 antibodies are essential tools for detecting and quantifying APOA1 in research and diagnostics. They are widely used in techniques like ELISA, Western blot, and immunohistochemistry to study APOA1 expression, HDL composition, and its association with diseases such as coronary artery disease, Alzheimer’s disease, and chronic kidney disease. Mutations or dysregulation of APOA1 can disrupt HDL function, making these antibodies valuable for investigating disease mechanisms or evaluating therapeutic interventions targeting HDL metabolism.
Most APOA1 antibodies are raised in hosts like rabbits or mice, with monoclonal antibodies offering high specificity and polyclonal antibodies providing broader epitope recognition. Validated antibodies are crucial for ensuring accuracy in both basic research and clinical applications, such as assessing cardiovascular risk profiles or developing HDL-based therapies. Their role in elucidating APOA1’s structure-function relationships continues to drive advancements in metabolic and cardiovascular research.
×
